Perceptive Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Perceptive Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-940	Closed	-$2K	–	180
2017 Q1	$2K	Sell	940 -292,520	-100%	-$1.32M	﹤0.01%	159
2016 Q4	$1.52M	Hold	293,460	–	–	0.11%	87
2016 Q3	$1.64M	Sell	293,460 -6,540	-2%	-$37.3K	0.11%	93
2016 Q2	$1.67M	Buy	+300,000	New	+$1.58M	0.12%	90
2015 Q3	–	Sell	-465,225	Closed	-$2.85M	–	201
2015 Q2	$2.85M	Sell	465,225 -174,000	-27%	-$1.35M	0.17%	86
2015 Q1	$5.15M	Buy	639,225 +125,001	+24%	+$943K	0.4%	50
2014 Q4	$2.6M	Buy	514,224 +459,151	+834%	+$2.27M	0.22%	80
2014 Q3	$286K	Hold	55,073	–	–	0.03%	95
2014 Q2	$428K	Sell	55,073 -6,190	-10%	-$43.7K	0.04%	89
2014 Q1	$428K	Hold	61,263	–	–	0.05%	95
2013 Q4	$367K	Sell	61,263 -88,737	-59%	-$580K	0.04%	78
2013 Q3	$1.17M	Hold	150,000	–	–	0.1%	68
2013 Q2	$570K	Buy	+150,000	New	+$615K	0.06%	66

Other funds holding GNMX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Perceptive Advisors's GNMX Position: Q2 2017 in Review

Perceptive Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 940 shares — an estimated $2K sold.

Perceptive Advisors first reported a position in GNMX in Q2 2013 and held it in 13 quarters. The position peaked at $5.15M in Q1 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

Perceptive Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
Perceptive Advisors sold 940 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $2K.
Perceptive Advisors first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 13 quarters.
Perceptive Advisors's Aevi Genomic Medicine Inc position peaked at $5.15M in Q1 2015.
51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.